Biogen Idec Looks To Develop PML Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
Alnylam’s RNAi technology will be directed at progressive multifocal leukoencephalopathy, the brain disease associated with Biogen’s MS therapy Tysabri.